More News! 8 Feb 2017
The FDA lays down Laws of Interchangeability: New Era for Biosimilars?
The new guidelines from the FDA on interchangeability may bring the US biosimilar market up to speed and a new opportunity for European companies. Though the US has long been seen as the most promising market for biosimilars due to the size of the market and high drug prices driving an interest in more affordable options, […]